


## Firmonertinib mesylate

Cat. No.:	HY-112870A
CAS No.:	2130958-55-1
Molecular Formula:	C <sub>29</sub> H <sub>35</sub> F <sub>3</sub> N <sub>8</sub> O <sub>5</sub> S
Molecular Weight:	664.7
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	4°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.	



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 5 mg/mL (7.52 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		1.5044 mL	7.5222 mL	15.0444 mL
		5 mM		0.3009 mL	1.5044 mL	3.0089 mL
		10 mM		---	---	---
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	Firmonertinib (Alflutinib) mesylate is a potent inhibitor of EGFR. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) <sup>[1]</sup> .
IC <sub>50</sub> & Target	EGFR
In Vitro	Firmonertinib mesylate can inhibit EGFR active mutations as well as the T790M acquired resistant mutation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- JTO Clin Res Rep. 2023 Nov 27, 100614.
- Patent. US20220177473A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA